Variable | Week | Secukinumab 10 mg/kg IV→150 mg SC(N=161) | Secukinumab 10 mg/kg IV→75 mg SC(N=147) |
PASI 75*†, % responders | 52 | 87.6 | 75.6 |
104 | 81.9 | 72.2 | |
156 | 75.6 | 58.6 | |
DAS28-CRP‡, mean change from baseline ±SD | 52 | −1.82±1.14 | −1.95±1.14 |
104 | −1.81±1.23 | −1.86±1.22 | |
156 | −1.94±1.32 | −1.85±1.49 | |
SF-36 PCS‡, mean change from baseline ±SD | 52 | 6.83±7.42 | 5.87±7.04 |
104 | 6.25±8.04 | 5.33±7.22 | |
156 | 6.01±8.53 | 5.50±7.27 | |
SF-36 MCS‡, mean change from baseline ±SD | 52 | 6.60±9.48 | 4.52±8.81 |
104 | 5.90±9.75 | 4.45±8.88 | |
156 | 5.48±10.29 | 3.34±9.64 | |
HAQ-DI‡, mean change from baseline ±SD | 52 | −0.47±0.51 | −0.47±0.60 |
104 | −0.43±0.56 | −0.42±0.60 | |
156 | −0.43±0.57 | −0.42±0.62 | |
ACR70*, % responders | 52 | 27.5 | 27.4 |
104 | 28.1 | 23.7 | |
156 | 32.9 | 26.0 | |
Dactylitis resolution*§ (%) | 52 | 82.0 | 84.4 |
104 | 86.5 | 88.6 | |
156 | 88.1 | 86.8 | |
Enthesitis resolution*§ (%) | 52 | 74.8 | 75.6 |
104 | 74.5 | 80.3 | |
156 | 76.7 | 74.8 | |
MDA*, % responders | 52 | 42.5 | 37.8 |
104 | 40.0 | 36.5 | |
156 | 42.9 | 33.3 |
*Multiple imputation applied to missing variables through week 156.
†Analysis performed in randomised patients with psoriasis affecting ≥3% body surface area (psoriasis subset).
‡Observed data through week 156.
§Resolution of dactylitis and enthesitis are shown for patients with these symptoms at baseline (dactylitis: N=83 (150 mg) and 77 (75 mg); enthesitis: N=99 (150 mg) and 91 (75 mg). Results are mean±SD unless otherwise stated.
ACR, American College of Rheumatology; DAS28-CRP, Disease Activity Score in 28 joints using C-reactive protein; HAQ-DI, Health Assessment Questionnaire–Disability Index; IV, intravenous; MCS, mental component summary; MDA, minimal disease activity; N, number of randomised patients; PASI, Psoriasis Area and Severity Index; PCS, physical component summary; SC, subcutaneous; SF-36, medical outcomes study 36-item Short Form-36 Health Survey.